Characteristics of Patients Initiated on Budesonide/Glycopyrronium Bromide/Formoterol Fumarate Single Inhaler Triple Therapy for the Treatment of Chronic Obstructive Pulmonary Disease: A Population-Based Observational Study
The majority of COPD patients are prescribed BUD/GLY/FOR triple therapy in accordance with current treatment guidelines, irrespective of whether the therapy is prescribed by a general practitioner or a pulmonologist.
Authors
- Elina Salmi
- Caroline Eteve‐Pitsaer
- Adrien Coriat
- Nicola J. Adderley (ORCID: https://orcid.org/0000-0003-0543-3254)
- Henri Leleu (ORCID: https://orcid.org/0000-0003-4930-6767)
- Nolwenn Poccardi
- C. Fabry-Vendrand (ORCID: https://orcid.org/0000-0001-8786-7843)
- Gaëtan Deslée (ORCID: https://orcid.org/0000-0002-4919-5916)
- Idir Ghout
Institutions
- Inserm (FR)
- Cegedim (France) (FR)
- ENOES (FR)
- Centre Hospitalier Universitaire de Reims (FR)
- AstraZeneca (France) (FR)
- University of Birmingham (GB)
- Université de Reims Champagne-Ardenne (FR)
Publication Details
- Journal
- International Journal of COPD
- Published
- 2025-04-01
- DOI
- https://doi.org/10.2147/copd.s495086
- Primary Topic
- Inhalation and Respiratory Drug Delivery
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- AstraZeneca